[go: up one dir, main page]

IN2014KN01716A - - Google Patents

Info

Publication number
IN2014KN01716A
IN2014KN01716A IN1716KON2014A IN2014KN01716A IN 2014KN01716 A IN2014KN01716 A IN 2014KN01716A IN 1716KON2014 A IN1716KON2014 A IN 1716KON2014A IN 2014KN01716 A IN2014KN01716 A IN 2014KN01716A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01716A publication Critical patent/IN2014KN01716A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1716KON2014 2012-02-21 2013-02-21 IN2014KN01716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035491 2012-02-21
PCT/JP2013/054345 WO2013125640A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
IN2014KN01716A true IN2014KN01716A (es) 2015-10-23

Family

ID=49005817

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1716KON2014 IN2014KN01716A (es) 2012-02-21 2013-02-21

Country Status (17)

Country Link
US (1) US9266958B2 (es)
EP (1) EP2824114B1 (es)
JP (1) JP6187258B2 (es)
KR (1) KR102009236B1 (es)
CN (1) CN104114583B (es)
AU (1) AU2013223147B2 (es)
BR (1) BR112014021103A2 (es)
CA (1) CA2865020C (es)
DK (1) DK2824114T3 (es)
ES (1) ES2739380T3 (es)
HU (1) HUE045461T2 (es)
IN (1) IN2014KN01716A (es)
MX (1) MX360211B (es)
PL (1) PL2824114T3 (es)
PT (1) PT2824114T (es)
RU (1) RU2633505C2 (es)
WO (1) WO2013125640A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
RU2603742C2 (ru) * 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
EP2741085B1 (en) * 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
BR112014002619A2 (pt) * 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
DK2818483T3 (en) 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
ES2656620T3 (es) * 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
CN104471403B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
JP7011764B2 (ja) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体アジュバント複合体
CN109890417A (zh) 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物
CA3095719A1 (en) 2018-03-30 2019-10-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
MX2021015221A (es) 2019-06-13 2022-03-17 Bolt Biotherapeutics Inc Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
WO2021067242A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
JP7709431B2 (ja) 2019-10-25 2025-07-16 ボルト バイオセラピューティクス、インコーポレーテッド チエノアゼピン、イムノコンジュゲート、及びそれらの使用
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119158A4 (en) 2020-03-12 2024-05-08 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
BR112022018171A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20230139178A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2022036101A1 (en) 2020-08-13 2022-02-17 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117545508A (zh) 2021-06-23 2024-02-09 东丽株式会社 用于癌的治疗和/或预防的药品
KR20240042415A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2023008462A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び/又は予防のための医薬品
JPWO2023008459A1 (es) 2021-07-27 2023-02-02
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
KR20250031149A (ko) 2022-06-30 2025-03-06 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119744176A (zh) 2022-08-24 2025-04-01 东丽株式会社 用于癌的治疗和/或预防的药品
AU2023329563A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4582100A1 (en) 2022-08-30 2025-07-09 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2024135809A1 (ja) 2022-12-23 2024-06-27 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
TR200002885T2 (tr) 1998-04-03 2000-12-21 Chugai Seiyaku Kabushiki Kaisha İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
EP1097208A2 (en) 1998-07-14 2001-05-09 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU1438001A (en) 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 27 human secreted proteins
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN100448992C (zh) 2001-05-11 2009-01-07 麒麟医药株式会社 含人抗体λ轻链基因的人类人工染色体
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
CN1681927A (zh) 2002-07-12 2005-10-12 加利福尼亚大学董事会 改进的转运蛋白及其用途
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
CA2504144A1 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
WO2005116076A2 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
JP4734319B2 (ja) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
ATE515515T1 (de) 2004-03-30 2011-07-15 Glaxo Group Ltd Immunglobuline gegen menschlisches osm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
EP1869462B1 (en) 2005-03-11 2013-05-08 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
IL274393B (en) 2008-03-18 2022-09-01 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
DK2325648T3 (da) * 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
DK2837383T3 (en) 2008-08-05 2017-03-20 Toray Industries Immunity Inducing Agent
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
CN102597001B (zh) 2009-08-19 2014-07-30 默克专利有限公司 在ffpe材料中用于检测整联蛋白复合体的抗体
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
RU2603742C2 (ru) * 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
EP2532364B1 (en) * 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
ES2691738T3 (es) 2010-02-04 2018-11-28 Toray Industries, Inc. Agente farmacéutico para el tratamiento y/o la prevención de cáncer
MX340017B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CN102821788B (zh) 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
WO2012013609A1 (en) 2010-07-26 2012-02-02 Bioréalités S.A.S. Methods and compositions for liver cancer therapy
JP5565183B2 (ja) 2010-08-06 2014-08-06 宇部興産株式会社 フィルムの製造方法
MX351682B (es) * 2011-08-04 2017-10-25 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物

Also Published As

Publication number Publication date
CA2865020C (en) 2021-01-26
MX360211B (es) 2018-10-24
PT2824114T (pt) 2019-08-05
BR112014021103A8 (pt) 2018-01-23
HUE045461T2 (hu) 2019-12-30
CN104114583A (zh) 2014-10-22
AU2013223147B2 (en) 2017-10-05
US20150017172A1 (en) 2015-01-15
US9266958B2 (en) 2016-02-23
CN104114583B (zh) 2019-11-19
WO2013125640A1 (ja) 2013-08-29
JPWO2013125640A1 (ja) 2015-07-30
EP2824114B1 (en) 2019-05-22
CA2865020A1 (en) 2013-08-29
EP2824114A1 (en) 2015-01-14
RU2014138038A (ru) 2016-04-10
EP2824114A4 (en) 2015-10-07
PL2824114T3 (pl) 2019-11-29
AU2013223147A1 (en) 2014-09-11
KR102009236B1 (ko) 2019-08-09
RU2633505C2 (ru) 2017-10-12
ES2739380T3 (es) 2020-01-30
BR112014021103A2 (pt) 2019-10-15
DK2824114T3 (da) 2019-07-29
MX2014009749A (es) 2014-11-14
JP6187258B2 (ja) 2017-08-30
KR20140130671A (ko) 2014-11-11

Similar Documents

Publication Publication Date Title
IN2014KN01713A (es)
IN2014KN01714A (es)
IN2014KN01716A (es)
IN2014KN01715A (es)
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
MX360671B (es) Composición farmacéutica para el tratamiento y/o prevención del cáncer.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
NZ705370A (en) Fcγriib-specific fc region variant
MY167232A (en) Polypeptides binding to human complement c5
MX2016008989A (es) Fragmentos mutantes de ospa y metodos y usos relacionados con estos.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
IN2014DN09963A (es)
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
GB201118201D0 (en) Novel peptides
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
WO2014039074A3 (en) Therapeutic compositions and related methods